X0508 4 2023-10-02 0 0001484565 SOLENO THERAPEUTICS INC SLNO 0001422484 Mackaness James H 203 REDWOOD SHORES PKWY, STE 500 REDWOOD CITY CA 94065 0 1 0 0 Chief Financial Officer 0 Common Stock 2023-10-02 4 M 0 2666 4.50 A 36236 D Common Stock 2023-10-02 4 M 0 2143 1.75 A 38379 D Common Stock 2023-10-02 4 M 0 3500 2.50 A 41879 D Warrants (right to buy) 4.50 2023-10-02 4 M 0 2666 0.00 D 2022-03-31 2027-03-31 Common Stock 2666 0 D Warrants (right to buy) 1.75 2023-10-02 4 M 0 2143 0.4425 D 2023-05-08 Common Stock 2143 0 D Warrants (right to buy) 2.50 2023-10-02 4 M 0 3500 0.4425 D 2023-05-08 Common Stock 3500 0 D The number of shares reported as beneficially owned following the reported transaction is as of October 2, 2023. The Warrants expire upon the earlier of (i) 30 days following announcement of positive top-line data from the randomized withdrawal period of Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS), or (ii) November 8, 2026. The Warrants expire upon the earlier of (i) 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS or (ii) November 8, 2026. /s/ James Mackaness 2023-12-13